- $8.09bn
- $7.15bn
- 54
- 19
- 46
- 33
Annual income statement for Nuvalent, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 16.9 | 45.8 | 86.1 | 149 | 280 |
| Operating Profit | -16.9 | -45.8 | -86.1 | -149 | -280 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -14.6 | -46.3 | -81.9 | -126 | -260 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -14.6 | -46.3 | -81.9 | -126 | -261 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -14.6 | -46.3 | -81.9 | -126 | -261 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -14.6 | -46.3 | -81.9 | -126 | -261 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.311 | -0.959 | -1.65 | -2.17 | -3.93 |